Sarah Koushyar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sarah Koushyar has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Arfon Gethyn Morgan Tregellis Powell
Greater Manchester Oesophagogastric Surgery Unit, Salford Royal Hospital, Salford, United Kingdom
1 shared publication D. Alwyn Dart
Cardiff China Medical Research Collaborative (CCMRC), Cardiff University, School of Medicine, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, UK
1 shared publication- Elizabeth Vincan
Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
1 shared publication - Toby James Phesse
The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
1 shared publication - Wen Guo Jiang
Cardiff University
1 shared publication
Latest Publications
- Open Access
- 30 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (11) , 3927
Targeting Wnt Signaling for the Treatment of Gastric Cancer
The Wnt signaling pathway is evolutionarily conserved, regulating both embryonic development and maintaining adult tissue homeostasis. Wnt signaling controls several fundamental cell functions, including proliferation, differentiation, migration, and stemness. It therefore plays an important role in the epithelial homeostasis and regeneration of the gastrointestinal tract. Often, both hypo- or hyper-activation of the pathway due to genetic, epigenetic, or receptor/ligand alterations are seen in many solid cancers, such as breast, colorectal, gastric, and prostate. Gastric cancer (GC) is the fourth commonest cause of cancer worldwide and is the second leading cause of cancer-related death annually. Although the number of new diagnoses has declined over recent decades, prognosis remains poor, with only 15% surviving to five years. Geographical differences in clinicopathological features are also apparent, with epidemiological and genetic studies revealing GC to be a highly heterogeneous disease with phenotypic diversity as a result of etiological factors. The molecular heterogeneity associated with GC dictates that a single ‘one size fits all’ approach to management is unlikely to be successful. Wnt pathway dysregulation has been observed in approximately 50% of GC tumors and may offer a novel therapeutic target for patients who would otherwise have a poor outcome. This mini review will highlight some recent discoveries involving Wnt signaling in GC.
- 30 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (11) , 3927
Open AccessTargeting Wnt Signaling for the Treatment of Gastric Cancer
The Wnt signaling pathway is evolutionarily conserved, regulating both embryonic development and maintaining adult tissue homeostasis. Wnt signaling controls several fundamental cell functions, including proliferation, differentiation, migration, and stemness. It therefore plays an important role in the epithelial homeostasis and regeneration of the gastrointestinal tract. Often, both hypo- or hyper-activation of the pathway due to genetic, epigenetic, or receptor/ligand alterations are seen in many solid cancers, such as breast, colorectal, gastric, and prostate. Gastric cancer (GC) is the fourth commonest cause of cancer worldwide and is the second leading cause of cancer-related death annually. Although the number of new diagnoses has declined over recent decades, prognosis remains poor, with only 15% surviving to five years. Geographical differences in clinicopathological features are also apparent, with epidemiological and genetic studies revealing GC to be a highly heterogeneous disease with phenotypic diversity as a result of etiological factors. The molecular heterogeneity associated with GC dictates that a single ‘one size fits all’ approach to management is unlikely to be successful. Wnt pathway dysregulation has been observed in approximately 50% of GC tumors and may offer a novel therapeutic target for patients who would otherwise have a poor outcome. This mini review will highlight some recent discoveries involving Wnt signaling in GC.
- Open Access
- 1 December 2015
- Published by Elsevier in Cancer Letters
- Vol. 369 (2) , 316-322
Unveiling the potential of prohibitin in cancer
- 1 December 2015
- Published by Elsevier in Cancer Letters
- Vol. 369 (2) , 316-322
Open AccessUnveiling the potential of prohibitin in cancer